메뉴 건너뛰기




Volumn 23, Issue 9, 2014, Pages 1211-1223

Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus

Author keywords

ACH 3422; ALS 2200; BMS 986094; EP NI266; IFN free; LG 7501; Mericitabine; NS5B; Sofosbuvir; VX 135

Indexed keywords

ACH 3422; ALS 2200; BMS 986094; EP NI 266; GS 6620; LG 7501; MERICITABINE; NUCLEOSIDE DERIVATIVE; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SOFOSBUVIR; UNCLASSIFIED DRUG; VX 135; 2-((5-(2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YLMETHOXY)PHENOXYPHOSPHORYLAMINO)PROPIONIC ACID ISOPROPYL ESTER; ANTIVIRUS AGENT; ENZYME INHIBITOR; URIDINE PHOSPHATE;

EID: 84903774295     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.921680     Document Type: Review
Times cited : (33)

References (119)
  • 1
    • 84906049978 scopus 로고    scopus 로고
    • Available from Last accessed 17 January 2014]
    • Hepatitis C. WHO. 2013.Available from: Http://www.who. int/mediacentre/factsheets/fs164/en/index. html [Last accessed 17 January 2014]
    • (2013) Hepatitis C. WHO
  • 2
    • 84894707183 scopus 로고    scopus 로고
    • Expanded classification of hepatitis C Virus into 7 genotypes and 67 Subtypes: Updated criteria and assignment web resource
    • Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C Virus into 7 genotypes and 67 Subtypes: Updated criteria and assignment web resource. Hepatology 2013;1:318-27
    • (2013) Hepatology , vol.1 , pp. 318-327
    • Smith, D.B.1    Bukh, J.2    Kuiken, C.3
  • 3
    • 84885799512 scopus 로고    scopus 로고
    • HCV-related autoimmune disorders in HCV chronic infection
    • Ferrari SM, Fallahi P, Mancusi C, et al. HCV-related autoimmune disorders in HCV chronic infection. Clin Ter 2013;164:e305-12
    • (2013) Clin ter
    • Ferrari, S.M.1    Fallahi, P.2    Mancusi, C.3
  • 4
    • 83855160892 scopus 로고    scopus 로고
    • Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy
    • Coppola N, Pisaturo M, Guastafierro S, et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig Liver Dis 2012;44:49-54
    • (2012) Dig Liver Dis , vol.44 , pp. 49-54
    • Coppola, N.1    Pisaturo, M.2    Guastafierro, S.3
  • 5
    • 84879798869 scopus 로고    scopus 로고
    • Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C
    • Zampino R CN, Cirillo G, Boemio A, et al. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. J Viral Hepat 2013;20:517-23
    • (2013) J Viral Hepat , vol.20 , pp. 517-523
    • Zampino, R.C.N.1    Cirillo, G.2    Boemio, A.3
  • 6
    • 84888855025 scopus 로고    scopus 로고
    • Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells
    • Coppola N, De Pascalis S, Pisaturo M, et al. Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells. J Clin Virol 2013;58(4):748-50
    • (2013) J Clin Virol , vol.58 , Issue.4 , pp. 748-750
    • Coppola, N.1    De Pascalis, S.2    Pisaturo, M.3
  • 8
    • 84887924285 scopus 로고    scopus 로고
    • Erectile dysfunction in patients with chronic viral hepatitis: A systematic review of the literature
    • Fusco F, DAnzeo G, Rossi A, et al. Erectile dysfunction in patients with chronic viral hepatitis: A systematic review of the literature. Expert Opin Pharmacother 2013;14:2533-44
    • (2013) Expert Opin Pharmacother , vol.14 , pp. 2533-2544
    • Fusco, F.1    Danzeo, G.2    Rossi, A.3
  • 9
    • 78751621217 scopus 로고    scopus 로고
    • Evolving epidemiology of hepatitis C virus
    • Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107-15
    • (2011) Clin Microbiol Infect , vol.17 , pp. 107-115
    • Lavanchy, D.1
  • 10
    • 0030928695 scopus 로고    scopus 로고
    • Hepatitis C the clinical spectrum of disease
    • Hoofnagle JH. Hepatitis C: The clinical spectrum of disease. Hepatology 1997;26:15S-20S
    • (1997) Hepatology , vol.26
    • Hoofnagle, J.H.1
  • 11
    • 84882779407 scopus 로고    scopus 로고
    • Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C
    • Sagnelli E, Pisaturo M, Stanzione M, et al. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol 2013;11:1174-80
    • (2013) Clin Gastroenterol Hepatol , vol.11 , pp. 1174-1180
    • Sagnelli, E.1    Pisaturo, M.2    Stanzione, M.3
  • 12
    • 84893696310 scopus 로고    scopus 로고
    • Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C
    • Coppola N, Gentile I, Pasquale G, et al. Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. Ann Hepatol 2014;13:20-6
    • (2014) Ann Hepatol , vol.13 , pp. 20-26
    • Coppola, N.1    Gentile, I.2    Pasquale, G.3
  • 13
    • 84877647206 scopus 로고    scopus 로고
    • A simple noninvasive score based on routine parameters can predict liver cirrhosis in patients with chronic Hepatitis C
    • Gentile I, Coppola N, Pasquale G, et al. A simple noninvasive score based on routine parameters can predict liver cirrhosis in patients with chronic Hepatitis C. Hepat Mon 2013;13:e8352
    • (2013) Hepat Mon , vol.13
    • Gentile, I.1    Coppola, N.2    Pasquale, G.3
  • 14
    • 40749111024 scopus 로고    scopus 로고
    • Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes
    • Fortunato G, Calcagno G, Bresciamorra V, et al. Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J Interferon Cytokine Res 2008;28:141-52
    • (2008) J Interferon Cytokine Res , vol.28 , pp. 141-152
    • Fortunato, G.1    Calcagno, G.2    Bresciamorra, V.3
  • 15
    • 0034859335 scopus 로고    scopus 로고
    • Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis
    • Fortunato G, Castaldo G, Oriani G, et al. Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. Clin Chem 2001;47:1696-700
    • (2001) Clin Chem , vol.47 , pp. 1696-1700
    • Fortunato, G.1    Castaldo, G.2    Oriani, G.3
  • 16
    • 84892722703 scopus 로고    scopus 로고
    • Human platelet antigen-3 genotype predicts platelet count in patients with HCV infection
    • Gentile I, Meola M, Buonomo AR, et al. Human platelet antigen-3 genotype predicts platelet count in patients with HCV infection. In Vivo 2013;27:773-7
    • (2013) Vivo , vol.27 , pp. 773-777
    • Gentile, I.1    Meola, M.2    Buonomo, A.R.3
  • 17
    • 0035206140 scopus 로고    scopus 로고
    • Does HIV infection favor the sexual transmission of hepatitis C?
    • Filippini P, Coppola N, Scolastico C, et al Does HIV infection favor the sexual transmission of hepatitis C? Sex Transm Dis 2001;28:725-9
    • (2001) Sex Transm Dis , vol.28 , pp. 725-729
    • Filippini, P.1    Coppola, N.2    Scolastico, C.3
  • 18
    • 2942626249 scopus 로고    scopus 로고
    • Influence of chronic coinfection with hepatitis B and C virus on liver histology
    • Sagnelli E, Pasquale G, Coppola N, et al. Influence of chronic coinfection with hepatitis B and C virus on liver histology. Infection 2004;32:144-8
    • (2004) Infection , vol.32 , pp. 144-148
    • Sagnelli, E.1    Pasquale, G.2    Coppola, N.3
  • 19
    • 84897421294 scopus 로고    scopus 로고
    • Is it possible to predict HCVrelated liver cirrhosis non-invasively through routine laboratory parameters?
    • Gentile I, Buonomo AR, Zappulo E, et al Is it possible to predict HCVrelated liver cirrhosis non-invasively through routine laboratory parameters? Infez Med 2014;22:11-18
    • (2014) Infez Med , vol.22 , pp. 11-18
    • Gentile, I.1    Buonomo, A.R.2    Zappulo, E.3
  • 20
    • 20044375378 scopus 로고    scopus 로고
    • The importance of HCV on the burden of chronic liver disease in Italy: A multicenter prevalence study of 9,997 cases
    • Sagnelli E, Stroffolini T, Mele A, et al. The importance of HCV on the burden of chronic liver disease in Italy: A multicenter prevalence study of 9,997 cases. J Med Virol 2005;75:522-7
    • (2005) J Med Virol , vol.75 , pp. 522-527
    • Sagnelli, E.1    Stroffolini, T.2    Mele, A.3
  • 21
    • 84878020247 scopus 로고    scopus 로고
    • Age and gender distribution of hepatitis C virus genotypes in the metropolitan area of Naples
    • Petruzziello A, Coppola N, Diodato AM, et al. Age and gender distribution of hepatitis C virus genotypes in the metropolitan area of Naples. Intervirology 2013;56:206-12
    • (2013) Intervirology , vol.56 , pp. 206-212
    • Petruzziello, A.1    Coppola, N.2    Diodato, A.M.3
  • 22
    • 84983122789 scopus 로고    scopus 로고
    • Hepatitis C virus infection in an endemic area of Southern Italy 14 years later: Evidence for a vanishing infection
    • Guadagnino V, Stroffolini T, Caroleo B, et al. Hepatitis C virus infection in an endemic area of Southern Italy 14 years later: Evidence for a vanishing infection. Dig Liver Dis 2013;45:403-7
    • (2013) Dig Liver Dis , vol.45 , pp. 403-407
    • Guadagnino, V.1    Stroffolini, T.2    Caroleo, B.3
  • 23
    • 12644279860 scopus 로고    scopus 로고
    • Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: A community-based survey in southern Italy
    • Guadagnino V, Stroffolini T, Rapicetta M, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: A community-based survey in southern Italy. Hepatology 1997;26:1006-11
    • (1997) Hepatology , vol.26 , pp. 1006-1011
    • Guadagnino, V.1    Stroffolini, T.2    Rapicetta, M.3
  • 24
    • 84878750736 scopus 로고    scopus 로고
    • Acute hepatitis C in patients undergoing hemodialysis: Experience with high-dose interferon therapy
    • Gentile I, Di Flumeri G, Scarica S, et al. Acute hepatitis C in patients undergoing hemodialysis: Experience with high-dose interferon therapy. Minerva Urol Nefrol 2013;65:83-4
    • (2013) Minerva Urol Nefrol , vol.65 , pp. 83-84
    • Gentile, I.1    Di Flumeri, G.2    Scarica, S.3
  • 25
    • 84879126730 scopus 로고    scopus 로고
    • Association of tattooing and hepatitis C virus infection: A multicenter case-control study
    • Carney K, Dhalla S, Aytaman A, et al. Association of tattooing and hepatitis C virus infection: A multicenter case-control study. Hepatology 2013;57:2117-23
    • (2013) Hepatology , vol.57 , pp. 2117-2123
    • Carney, K.1    Dhalla, S.2    Aytaman, A.3
  • 26
    • 72049112561 scopus 로고    scopus 로고
    • Improvement in the aetiological diagnosis of acute hepatitis C: A diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index
    • Coppola N, Pisapia R, Tonziello G, et al. Improvement in the aetiological diagnosis of acute hepatitis C: A diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index. J Clin Virol 2009;46:222-9
    • (2009) J Clin Virol , vol.46 , pp. 222-229
    • Coppola, N.1    Pisapia, R.2    Tonziello, G.3
  • 27
    • 34548693175 scopus 로고    scopus 로고
    • Anti-HCV IgG avidity index in acute hepatitis C
    • Coppola N, Pisapia R, Marrocco C, et al. Anti-HCV IgG avidity index in acute hepatitis C. J Clin Virol 2007;40:110-15
    • (2007) J Clin Virol , vol.40 , pp. 110-115
    • Coppola, N.1    Pisapia, R.2    Marrocco, C.3
  • 28
    • 84881451656 scopus 로고    scopus 로고
    • Concomitant interferon-Alpha and chemotherapy in hepatitis C and colorectal cancer: A case report
    • Gentile I, De Stefano A, Di Flumeri G, et al. Concomitant interferon-Alpha and chemotherapy in hepatitis C and colorectal cancer: A case report. In Vivo 2013;27:527-9
    • (2013) Vivo , vol.27 , pp. 527-529
    • Gentile, I.1    De Stefano, A.2    Di Flumeri, G.3
  • 29
    • 75149163334 scopus 로고    scopus 로고
    • Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression
    • Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138:513-21
    • (2010) Gastroenterology , vol.138 , pp. 513-521
    • Davis, G.L.1    Alter, M.J.2    El-Serag, H.3
  • 30
    • 67651174428 scopus 로고    scopus 로고
    • A simple noninvasive score predicts gastroesophageal varices in patients with chronic viral hepatitis
    • Gentile I, Viola C, Graf M, et al. A simple noninvasive score predicts gastroesophageal varices in patients with chronic viral hepatitis. J Clin Gastroenterol 2009;43:81-7
    • (2009) J Clin Gastroenterol , vol.43 , pp. 81-87
    • Gentile, I.1    Viola, C.2    Graf, M.3
  • 31
    • 77951648047 scopus 로고    scopus 로고
    • Surrogate endpoints and non-inferiority trials in chronic viral hepatitis
    • Gentile I, Borgia G. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. J Hepatol 2010;52:778
    • (2010) J Hepatol , vol.52 , pp. 778
    • Gentile, I.1    Borgia, G.2
  • 32
    • 35648970573 scopus 로고    scopus 로고
    • Effect of sustained virological response on long-Term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin
    • Braks RE, Ganne-Carrie N, Fontaine H, et al. Effect of sustained virological response on long-Term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007;13:5648-53
    • (2007) World J Gastroenterol , vol.13 , pp. 5648-5653
    • Braks, R.E.1    Ganne-Carrie, N.2    Fontaine, H.3
  • 33
    • 4644224871 scopus 로고    scopus 로고
    • Long-Term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy
    • Tsuda N, Yuki N, Mochizuki K, et al. Long-Term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J Med Virol 2004;74:406-13
    • (2004) J Med Virol , vol.74 , pp. 406-413
    • Tsuda, N.1    Yuki, N.2    Mochizuki, K.3
  • 34
    • 33947360829 scopus 로고    scopus 로고
    • Sustained virological response to interferon-Alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study
    • Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-Alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology 2007;45:579-87
    • (2007) Hepatology , vol.45 , pp. 579-587
    • Bruno, S.1    Stroffolini, T.2    Colombo, M.3
  • 35
    • 34548227085 scopus 로고    scopus 로고
    • Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: A randomized controlled trial
    • Di Marco V, Almasio PL, Ferraro D, et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: A randomized controlled trial. J Hepatol 2007;47:484-91
    • (2007) J Hepatol , vol.47 , pp. 484-491
    • Di Marco, V.1    Almasio, P.L.2    Ferraro, D.3
  • 36
    • 0037063113 scopus 로고    scopus 로고
    • Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection
    • Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347:89-94
    • (2002) N Engl J Med , vol.347 , pp. 89-94
    • Hermine, O.1    Lefrere, F.2    Bronowicki, J.P.3
  • 37
    • 84867802123 scopus 로고    scopus 로고
    • Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection
    • Takahashi K, Nishida N, Kawabata H, et al. Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection. Intern Med 2012;51:2745-7
    • (2012) Intern Med , vol.51 , pp. 2745-2747
    • Takahashi, K.1    Nishida, N.2    Kawabata, H.3
  • 38
    • 84877795646 scopus 로고    scopus 로고
    • Sustained virological response: A milestone in the treatment of chronic hepatitis C
    • Morisco F, Granata R, Stroffolini T, et al. Sustained virological response: A milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013;19:2793-8
    • (2013) World J Gastroenterol , vol.19 , pp. 2793-2798
    • Morisco, F.1    Granata, R.2    Stroffolini, T.3
  • 39
    • 84877782905 scopus 로고    scopus 로고
    • Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies
    • Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013;144:1450-5
    • (2013) Gastroenterology , vol.144 , pp. 1450-1455
    • Chen, J.1    Florian, J.2    Carter, W.3
  • 40
    • 79954669573 scopus 로고    scopus 로고
    • Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-Alfa based therapy
    • Lange CM, Bojunga J, Ramos-Lopez E, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-Alfa based therapy. J Hepatol 2011;54:887-93
    • (2011) J Hepatol , vol.54 , pp. 887-893
    • Lange, C.M.1    Bojunga, J.2    Ramos-Lopez, E.3
  • 41
    • 84896126011 scopus 로고    scopus 로고
    • Prediction of sustained virologic responses to combination therapy of pegylated interferon-Alpha and ribavirin in patients with chronic hepatitis C infection
    • Ismail MH. Prediction of sustained virologic responses to combination therapy of pegylated interferon-Alpha and ribavirin in patients with chronic hepatitis C infection. J Fam Community Med 2013;20:35-40
    • (2013) J Fam Community Med , vol.20 , pp. 35-40
    • Ismail, M.H.1
  • 42
    • 58149484038 scopus 로고    scopus 로고
    • Homocysteine levels and sustained virological response to pegylatedinterferon alpha2b plus ribavirin therapy for chronic hepatitis C: A prospective study
    • Borgia G, Gentile I, Fortunato G, et al. Homocysteine levels and sustained virological response to pegylatedinterferon alpha2b plus ribavirin therapy for chronic hepatitis C: A prospective study. Liver Int 2009;29:248-52
    • (2009) Liver Int , vol.29 , pp. 248-252
    • Borgia, G.1    Gentile, I.2    Fortunato, G.3
  • 43
    • 0035990966 scopus 로고    scopus 로고
    • Raised serum ferritin predicts nonresponse to interferon and ribavirin treatment in patients with chronic hepatitis C infection
    • Distante S, Bjoro K, Hellum KB, et al. Raised serum ferritin predicts nonresponse to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 2002;22:269-75
    • (2002) Liver , vol.22 , pp. 269-275
    • Distante, S.1    Bjoro, K.2    Hellum, K.B.3
  • 44
    • 70449601851 scopus 로고    scopus 로고
    • Iron depletion before HCV antiviral therapy: A pilot, randomized, controlled trial
    • Gentile I, Viola C, Paesano L, et al. Iron depletion before HCV antiviral therapy: A pilot, randomized, controlled trial. J Clin Apher 2009;24:190-6
    • (2009) J Clin Apher , vol.24 , pp. 190-196
    • Gentile, I.1    Viola, C.2    Paesano, L.3
  • 45
    • 83755196636 scopus 로고    scopus 로고
    • Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients
    • Abu-Mouch S, Fireman Z, Jarchovsky J, et al. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J Gastroenterol 2011;17:5184-90
    • (2011) World J Gastroenterol , vol.17 , pp. 5184-5190
    • Abu-Mouch, S.1    Fireman, Z.2    Jarchovsky, J.3
  • 46
    • 84857532001 scopus 로고    scopus 로고
    • Vitamin D improves viral response in hepatitis C genotype 2-3 naive patients
    • Nimer A, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naive patients. World J Gastroenterol 2012;18:800-5
    • (2012) World J Gastroenterol , vol.18 , pp. 800-805
    • Nimer, A.1    Mouch, A.2
  • 47
    • 84896959418 scopus 로고    scopus 로고
    • Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection
    • Coppola N, Marrone A, Pisaturo M, et al. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis 2014;33:559-67
    • (2014) Eur J Clin Microbiol Infect Dis , vol.33 , pp. 559-567
    • Coppola, N.1    Marrone, A.2    Pisaturo, M.3
  • 48
    • 33749241866 scopus 로고    scopus 로고
    • Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[ 1,1-dimethylethyl)amino] carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6- dimethyl-3-Azabicyclo [3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: A potential therapeutic agent for the treatment of hepatitis C infection
    • Venkatraman S, Bogen SL, Arasappan A, et al. Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1, 1-dimethylethyl)amino] carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3- Azabicyclo [3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: A potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem 2006;49:6074-86
    • (2006) J Med Chem , vol.49 , pp. 6074-6086
    • Venkatraman, S.1    Bogen, S.L.2    Arasappan, A.3
  • 49
    • 33646036163 scopus 로고    scopus 로고
    • Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034
    • Tong X, Chase R, Skelton A, et al. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006;70:28-38
    • (2006) Antiviral Res , vol.70 , pp. 28-38
    • Tong, X.1    Chase, R.2    Skelton, A.3
  • 50
    • 33744457959 scopus 로고    scopus 로고
    • Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease
    • Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006;6:3-16
    • (2006) Infect Disord Drug Targets , vol.6 , pp. 3-16
    • Lin, C.1    Kwong, A.D.2    Perni, R.B.3
  • 51
    • 65649142019 scopus 로고    scopus 로고
    • Telaprevir: A promising protease inhibitor for the treatment of hepatitis C virus infection
    • Gentile I, Viola C, Borgia F, et al. Telaprevir: A promising protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem 2009;16:1115-21
    • (2009) Curr Med Chem , vol.16 , pp. 1115-1121
    • Gentile, I.1    Viola, C.2    Borgia, F.3
  • 52
    • 84871109075 scopus 로고    scopus 로고
    • Efficacy of Pegylated interferon alpha-2a and alpha-2b in patients with genotype 1 chronic hepatitis C: A meta-Analysis
    • Coppola N, Pisaturo M, Tonziello G, et al. Efficacy of Pegylated interferon alpha-2a and alpha-2b in patients with genotype 1 chronic hepatitis C: A meta-Analysis. BMC Infect Dis 2012;12:1471-2334
    • (2012) BMC Infect Dis , vol.12 , pp. 1471-2334
    • Coppola, N.1    Pisaturo, M.2    Tonziello, G.3
  • 53
    • 65449136656 scopus 로고    scopus 로고
    • Diagnosis, management, and treatment of hepatitis C: An update
    • Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009;49:1335-74
    • (2009) Hepatology , vol.49 , pp. 1335-1374
    • Ghany, M.G.1    Strader, D.B.2    Thomas, D.L.3
  • 56
    • 84877739274 scopus 로고    scopus 로고
    • Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
    • Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-77
    • (2013) N Engl J Med , vol.368 , pp. 1867-1877
    • Jacobson, I.M.1    Gordon, S.C.2    Kowdley, K.V.3
  • 57
    • 84877730954 scopus 로고    scopus 로고
    • Sofosbuvir for previously untreated chronic hepatitis C infection
    • Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87
    • (2013) N Engl J Med , vol.368 , pp. 1878-1887
    • Lawitz, E.1    Mangia, A.2    Wyles, D.3
  • 58
    • 84896134666 scopus 로고    scopus 로고
    • Efficacy and safety of sofosbuvir in treatment of chronic hepatitis C: The dawn of the a new era
    • In press
    • Gentile I, Borgia F, Zappulo E, et al. Efficacy and safety of sofosbuvir in treatment of chronic hepatitis C: The dawn of the a new era. Rev Recent Clin Trials 2013; In press
    • (2013) Rev Recent Clin Trials
    • Gentile, I.1    Borgia, F.2    Zappulo, E.3
  • 59
    • 84892751187 scopus 로고    scopus 로고
    • Sofosbuvir + Ribavirin for 12 or 24 Weeks for Patients with HCV Genotype 2 or 3: The VALENCE trial
    • Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir + Ribavirin for 12 or 24 Weeks for Patients with HCV Genotype 2 or 3: The VALENCE trial. Hepatology 2013;58:733-4
    • (2013) Hepatology , vol.58 , pp. 733-734
    • Zeuzem, S.1    Dusheiko, G.M.2    Salupere, R.3
  • 60
    • 80053339008 scopus 로고    scopus 로고
    • An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
    • Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-44
    • (2011) Hepatology , vol.54 , pp. 1433-1444
    • Ghany, M.G.1    Nelson, D.R.2    Strader, D.B.3
  • 61
    • 84883404339 scopus 로고    scopus 로고
    • A novel promising therapeutic option against hepatitis C virus: An oral nucleotide NS5B polymerase inhibitor sofosbuvir
    • Gentile I, Borgia F, Buonomo AR, et al. A novel promising therapeutic option against hepatitis C virus: An oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem 2013;20:3733-42
    • (2013) Curr Med Chem , vol.20 , pp. 3733-3742
    • Gentile, I.1    Borgia, F.2    Buonomo, A.R.3
  • 62
    • 84856410313 scopus 로고    scopus 로고
    • Antiviral strategies in hepatitis C virus infection
    • Sarrazin C, Hezode C, Zeuzem S, et al. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012;56:S88-S100
    • (2012) J Hepatol , vol.56
    • Sarrazin, C.1    Hezode, C.2    Zeuzem, S.3
  • 63
    • 84898439254 scopus 로고    scopus 로고
    • Daclatasvir: The first of a new class of drugs targeted against hepatitis C virus NS5A
    • Gentile I, Borgia F, Coppola N, et al. Daclatasvir: The first of a new class of drugs targeted against hepatitis C virus NS5A. Curr Med Chem 2014;21:1391-404
    • (2014) Curr Med Chem , vol.21 , pp. 1391-1404
    • Gentile, I.1    Borgia, F.2    Coppola, N.3
  • 64
    • 84874107832 scopus 로고    scopus 로고
    • Perspectives and challenges of interferon-free therapy for chronic hepatitis C
    • Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013;58:583-92
    • (2013) J Hepatol , vol.58 , pp. 583-592
    • Lange, C.M.1    Zeuzem, S.2
  • 65
    • 84896138890 scopus 로고    scopus 로고
    • Ledipasvir : A novel synthetic antiviral for the treatment of HCV infection
    • Gentile I, Buonomo AR, Borgia F, et al. Ledipasvir : A novel synthetic antiviral for the treatment of HCV infection. Expert Opin Investig Drugs 2014;23:561-71
    • (2014) Expert Opin Investig Drugs , vol.23 , pp. 561-571
    • Gentile, I.1    Buonomo, A.R.2    Borgia, F.3
  • 66
    • 23944476834 scopus 로고    scopus 로고
    • Unravelling hepatitis C virus replication from genome to function
    • Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005;436:933-8
    • (2005) Nature , vol.436 , pp. 933-938
    • Lindenbach, B.D.1    Rice, C.M.2
  • 67
    • 36248994744 scopus 로고    scopus 로고
    • Specifically targeted antiviral therapy for hepatitis C virus
    • Parfieniuk A, Jaroszewicz J, Flisiak R. Specifically targeted antiviral therapy for hepatitis C virus. World J Gastroenterol 2007;13(43):5673-81
    • (2007) World J Gastroenterol , vol.13 , Issue.43 , pp. 5673-5681
    • Parfieniuk, A.1    Jaroszewicz, J.2    Flisiak, R.3
  • 68
    • 72049091527 scopus 로고    scopus 로고
    • The efficacy and safety of telaprevir-A new protease inhibitor against hepatitis C virus
    • Gentile I, Carleo MA, Borgia F, et al. The efficacy and safety of telaprevir-A new protease inhibitor against hepatitis C virus. Expert Opin Investig Drugs 2010;19:151-9
    • (2010) Expert Opin Investig Drugs , vol.19 , pp. 151-159
    • Gentile, I.1    Carleo, M.A.2    Borgia, F.3
  • 69
    • 84906057792 scopus 로고    scopus 로고
    • Different incorporation efficiencies for nucleotide analogs during HCV polymerase RNA synthesis initiation and elongation phases
    • Ma H, Inocencio N, Leveque V, et al. Different incorporation efficiencies for nucleotide analogs during HCV polymerase RNA synthesis initiation and elongation phases. Antiviral Res 2008;78:A22-3
    • (2008) Antiviral Res , vol.78
    • Ma, H.1    Inocencio, N.2    Leveque, V.3
  • 70
    • 82955236108 scopus 로고    scopus 로고
    • Anti-HCV drugs in the pipeline
    • Yang PL, Gao M, Lin K, et al. Anti-HCV drugs in the pipeline. Curr Opin Virol 2011;1:607-16
    • (2011) Curr Opin Virol , vol.1 , pp. 607-616
    • Yang, P.L.1    Gao, M.2    Lin, K.3
  • 71
    • 84898441875 scopus 로고    scopus 로고
    • MK-5172 : A second-generation protease inhibitor for the treatment of hepatitis C virus infection
    • Gentile I, Buonomo AR, Borgia F, et al. MK-5172 : A second-generation protease inhibitor for the treatment of hepatitis C virus infection. Expert Opin Investig Drugs 2014;23:719-28
    • (2014) Expert Opin Investig Drugs , vol.23 , pp. 719-728
    • Gentile, I.1    Buonomo, A.R.2    Borgia, F.3
  • 73
    • 84880659527 scopus 로고    scopus 로고
    • All-oral HCV therapies near approval
    • Tse MT. All-oral HCV therapies near approval. Nat Rev Drug Discov 2013;12(6):409-11
    • (2013) Nat Rev Drug Discov , vol.12 , Issue.6 , pp. 409-411
    • Tse, M.T.1
  • 74
    • 84877905656 scopus 로고    scopus 로고
    • Hepatitis C therapy with HCV NS5B polymerase inhibitors
    • Soriano V, Vispo E, De Mendoza C, et al. Hepatitis C therapy with HCV NS5B polymerase inhibitors. Expert Opin Pharmacother 2013;14:1161-70
    • (2013) Expert Opin Pharmacother , vol.14 , pp. 1161-1170
    • Soriano, V.1    Vispo, E.2    De Mendoza, C.3
  • 75
    • 84890947330 scopus 로고    scopus 로고
    • Novel therapeutic approaches for hepatitis C
    • Au JS, Pockros PJ. Novel therapeutic approaches for hepatitis C. Clin Pharmacol Ther 2014;95:78-88
    • (2014) Clin Pharmacol Ther , vol.95 , pp. 78-88
    • Au, J.S.1    Pockros, P.J.2
  • 76
    • 33646457538 scopus 로고    scopus 로고
    • Inhibition of hepatitis C replicon RNA synthesis by beta-D-2-deoxy-2- fluoro-2-C-methylcytidine: A specific inhibitor of hepatitis C virus replication
    • Stuyver LJ, McBrayer TR, Tharnish PM, et al. Inhibition of hepatitis C replicon RNA synthesis by beta-D-2-deoxy-2-fluoro-2-C-methylcytidine: A specific inhibitor of hepatitis C virus replication. Antivir Chem Chemother 2006;17:79-87
    • (2006) Antivir Chem Chemother , vol.17 , pp. 79-87
    • Stuyver, L.J.1    McBrayer, T.R.2    Tharnish, P.M.3
  • 77
    • 84906063038 scopus 로고    scopus 로고
    • Single-dose pharmacokinetics of the HCV polymerase inhibitor Mericitabine in Healthy Caucasian and Japanese Subjects
    • Washington C, Moreira S, Haznedar J, et al. Single-dose pharmacokinetics of the HCV polymerase inhibitor Mericitabine in Healthy Caucasian and Japanese Subjects. Drug Metab Pharmacokinet 2013;10:10
    • (2013) Drug Metab Pharmacokinet , vol.10 , pp. 10
    • Washington, C.1    Moreira, S.2    Haznedar, J.3
  • 78
    • 84885318167 scopus 로고    scopus 로고
    • The effect of mild to moderate renal impairment on the pharmacokinetics (PK of the hepatitis c virus (HCV) polymerase inhibitor mericitabine (MCB, RG7128)
    • Moreira S, Haznedar J, Marbury TC, et al. The effect of mild to moderate renal impairment on the pharmacokinetics (PK) of the hepatitis c virus (HCV) polymerase inhibitor mericitabine (MCB, RG7128). Hepatology 2011;54:537A-8A
    • (2011) Hepatology , vol.54
    • Moreira, S.1    Haznedar, J.2    Marbury, T.C.3
  • 79
    • 84906054487 scopus 로고    scopus 로고
    • No impact of cirrhosis on mericitabine (MCB pharmacokinetics and early antiviral activity in hepatitis C-infected patients receiving MCB plus peginterferon alfa-2a (40KD)/ribavirin (P/R)
    • Moreira S, Levi M, Kulkarni R, et al. No impact of cirrhosis on mericitabine (MCB) pharmacokinetics and early antiviral activity in hepatitis C-infected patients receiving MCB plus peginterferon alfa-2a (40KD)/ribavirin (P/R). Hepatology 2012;56:583A-A
    • (2012) Hepatology , vol.56
    • Moreira, S.1    Levi, M.2    Kulkarni, R.3
  • 80
    • 41349083638 scopus 로고    scopus 로고
    • Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy
    • Reddy R, Rodriguez-Torres M, Gane E, et al. Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology 2007;46:862A-3A
    • (2007) Hepatology , vol.46
    • Reddy, R.1    Rodriguez-Torres, M.2    Gane, E.3
  • 81
    • 46249112617 scopus 로고    scopus 로고
    • Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with Peg-IFN and ribavirin: Interim results of R7128 500mg BID for 28 days
    • Lalezari J, Gane E, Rodriguez-Torres M, et al. Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with Peg-IFN and ribavirin: Interim results of R7128 500mg BID for 28 days. J Hepatol 2008;48:S29
    • (2008) J Hepatol , vol.48
    • Lalezari, J.1    Gane, E.2    Rodriguez-Torres, M.3
  • 82
    • 84863396230 scopus 로고    scopus 로고
    • Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128
    • Guedj J, Dahari H, Shudo E, et al. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology 2012;55:1030-7
    • (2012) Hepatology , vol.55 , pp. 1030-1037
    • Guedj, J.1    Dahari, H.2    Shudo, E.3
  • 83
    • 59149098021 scopus 로고    scopus 로고
    • Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: Interim results of R7128 1500mg bid with PEG-IFN and ribavirin for 28 days
    • Gane EJ, Rodriguez-Torres M, Nelson DR, et al. Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: Interim results of R7128 1500mg bid with PEG-IFN and ribavirin for 28 days. Hepatology 2008;48:1024A-A
    • (2008) Hepatology , vol.48
    • Gane, E.J.1    Rodriguez-Torres, M.2    Nelson, D.R.3
  • 84
    • 77958162291 scopus 로고    scopus 로고
    • Sustained virologic response (SVR) following RG7128 1500mg bid/PEG-IFN/RBV for 28 days in HCV genotype 2/3 prior non-responders
    • Gane EJ, Rodriguez-Torres M, Nelson DE, et al. Sustained virologic response (SVR) following RG7128 1500mg bid/PEG-IFN/RBV for 28 days in HCV genotype 2/3 prior non-responders. J Hepatol 2010;52:S16
    • (2010) J Hepatol , vol.52
    • Gane, E.J.1    Rodriguez-Torres, M.2    Nelson, D.E.3
  • 85
    • 84879211393 scopus 로고    scopus 로고
    • PROPEL: A randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naive HCV genotype 1/4 patients
    • Wedemeyer H, Jensen D, Herring R Jr, et al. PROPEL: A randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naive HCV genotype 1/4 patients. Hepatology 2013;58:524-37
    • (2013) Hepatology , vol.58 , pp. 524-537
    • Wedemeyer, H.1    Jensen, D.2    Herring Jr., R.3
  • 86
    • 84881025292 scopus 로고    scopus 로고
    • JUMP-C: A randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naive HCV genotype 1/4 patients
    • Pockros PJ, Jensen D, Tsai N, et al. JUMP-C: A randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naive HCV genotype 1/4 patients. Hepatology 2013;58:514-23
    • (2013) Hepatology , vol.58 , pp. 514-523
    • Pockros, P.J.1    Jensen, D.2    Tsai, N.3
  • 87
    • 84894271490 scopus 로고    scopus 로고
    • In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir
    • Tong X, Le Pogam S, Li L, et al. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis 2014;209:668-75
    • (2014) J Infect Dis , vol.209 , pp. 668-675
    • Tong, X.1    Le Pogam, S.2    Li, L.3
  • 88
    • 78049527728 scopus 로고    scopus 로고
    • Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): A randomised, doubleblind, placebo-controlled, dose-escalation trial
    • Gane EJ, Roberts SK, Stedman CAM, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): A randomised, doubleblind, placebo-controlled, dose-escalation trial. Lancet 2010;376:1467-75
    • (2010) Lancet , vol.376 , pp. 1467-1475
    • Gane, E.J.1    Roberts, S.K.2    Stedman, C.A.M.3
  • 89
    • 84868029979 scopus 로고    scopus 로고
    • Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-Term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir
    • Le Pogam S, Yan JM, Chhabra M, et al. Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-Term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir. Antimicrob Agents Chemother 2012;56:5494-502
    • (2012) Antimicrob Agents Chemother , vol.56 , pp. 5494-5502
    • Le Pogam, S.1    Yan, J.M.2    Chhabra, M.3
  • 90
    • 78349268362 scopus 로고    scopus 로고
    • RG7128 alone or in combination with pegylated interferon-Alpha2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients
    • Le Pogam S, Seshaadri A, Ewing A, et al. RG7128 alone or in combination with pegylated interferon-Alpha2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients. J Infect Dis 2010;202:1510-19
    • (2010) J Infect Dis , vol.202 , pp. 1510-1519
    • Le Pogam, S.1    Seshaadri, A.2    Ewing, A.3
  • 91
    • 84878136958 scopus 로고    scopus 로고
    • Up to 100% SVR4 rates with ritonavirboosted danoprevir (DNVr), mericitabine (MCB) and ribavirin (R) +/-peginterferon alfa-2a (40KD) (P) in HCV genotype 1-infected partial and null responders: Results from the MATTERHORN study
    • Feld JJ, Jacobson IM, Jensen DM, et al. Up to 100% SVR4 rates with ritonavirboosted danoprevir (DNVr), mericitabine (MCB) and ribavirin (R) +/-peginterferon alfa-2a (40KD) (P) in HCV genotype 1-infected partial and null responders: Results from the MATTERHORN study. Hepatology 2012;56:231A-2A
    • (2012) Hepatology , vol.56
    • Feld, J.J.1    Jacobson, I.M.2    Jensen, D.M.3
  • 92
    • 84906064180 scopus 로고    scopus 로고
    • Interferon-free regimen containing setrobuvir (STV) in combination with ritonavir-boosted danoprevir (DNVr) and ribavirin (R) with or without mericitabine (MCB) in HCV genotype (G)1 treatment-naive patients: Interim SVR4 results from the ANNAPURNA study
    • Jensen DM, Brunda M, Elston R, et al. Interferon-free regimen containing setrobuvir (STV) in combination with ritonavir-boosted danoprevir (DNVr) and ribavirin (R) with or without mericitabine (MCB) in HCV genotype (G)1 treatment-naive patients: Interim SVR4 results from the ANNAPURNA study. Hepatology 2013;58:741A
    • (2013) Hepatology , vol.58
    • Jensen, D.M.1    Brunda, M.2    Elston, R.3
  • 93
    • 84884304405 scopus 로고    scopus 로고
    • Meeting report: 26th International Conference on Antiviral Research
    • Vere Hodge RA. Meeting report: 26th International Conference on Antiviral Research. Antiviral Res 2013;100:276-85
    • (2013) Antiviral Res , vol.100 , pp. 276-285
    • Vere Hodge, R.A.1
  • 94
    • 84906053170 scopus 로고    scopus 로고
    • Preclinical characterization of ALS-2200, a potent nucleotide polymerase inhibitor for the treatment of chronic hepatitis C
    • Tan H, Deval J, Kang H, et al. Preclinical characterization of ALS-2200, a potent nucleotide polymerase inhibitor for the treatment of chronic hepatitis C. Hepatology 2012;56:1069A-70A
    • (2012) Hepatology , vol.56
    • Tan, H.1    Deval, J.2    Kang, H.3
  • 95
    • 84906056707 scopus 로고    scopus 로고
    • In vitro resistance to ALS-2200, a potent nucleotide polymerase inhibitor for the treatment of chronic hepatitis C
    • Tan H, Jekle A, Kang H, et al. In vitro resistance to ALS-2200, a potent nucleotide polymerase inhibitor for the treatment of chronic hepatitis C. J Hepatol 2013;58:S496
    • (2013) J Hepatol , vol.58
    • Tan, H.1    Jekle, A.2    Kang, H.3
  • 96
    • 84898609302 scopus 로고    scopus 로고
    • Analysis of ALS-2200, a novel potent nucleotide analog, combination drug interactions in the hepatitis C virus (HCV) subgenomic replicon system
    • Tan H, Kang H, Moy C, et al. Analysis of ALS-2200, a novel potent nucleotide analog, combination drug interactions in the hepatitis C virus (HCV) subgenomic replicon system. Hepatology 2012;56:1072A-A
    • (2012) Hepatology , vol.56
    • Tan, H.1    Kang, H.2    Moy, C.3
  • 97
    • 84872037558 scopus 로고    scopus 로고
    • ALS-2200, a novel once-daily nucleotide HCV polymerase inhibitor, demonstrates potent antiviral activity over 7 days in treatment-naive genotype 1 (GT1) patients
    • Marcellin P, Popa S, Berliba A, et al. ALS-2200, a novel once-daily nucleotide HCV polymerase inhibitor, demonstrates potent antiviral activity over 7 days in treatment-naive genotype 1 (GT1) patients. Hepatology 2012;56:235A-A
    • (2012) Hepatology , vol.56
    • Marcellin, P.1    Popa, S.2    Berliba, A.3
  • 98
    • 84906058337 scopus 로고    scopus 로고
    • ALS-2200, a novel once-daily nucleotide HCV polymerase inhibitor, demonstrated potent antiviral activity in treatment-naive patients with compensated cirrhosis or genotype 2-4 chronic hepatitis C
    • Marcellin P, Popa S, Streinu-Cercel A, et al. ALS-2200, a novel once-daily nucleotide HCV polymerase inhibitor, demonstrated potent antiviral activity in treatment-naive patients with compensated cirrhosis or genotype 2-4 chronic hepatitis C. J Hepatol 2013;58:S355
    • (2013) J Hepatol , vol.58
    • Marcellin, P.1    Popa, S.2    Streinu-Cercel, A.3
  • 99
    • 84906046362 scopus 로고    scopus 로고
    • VX-135, a potent single diastereomer of ALS-2200, for the treatment of chronic hepatitis C
    • Tan H, Deval J, Kang H, et al. VX-135, a potent single diastereomer of ALS-2200, for the treatment of chronic hepatitis C. J Hepatol 2013;58:S495
    • (2013) J Hepatol , vol.58
    • Tan, H.1    Deval, J.2    Kang, H.3
  • 100
    • 84906054914 scopus 로고    scopus 로고
    • VX-135, a once-daily nucleotide HCV polymerase inhibitor, was well tolerated and demonstrated potent antiviral activity when given with ribavirin in treatment-naïve patients with genotype 1 HCV
    • Popa S, Berliba A, Ghicavii N, et al. VX-135, a once-daily nucleotide HCV polymerase inhibitor, was well tolerated and demonstrated potent antiviral activity when given with ribavirin in treatment-naïve patients with genotype 1 HCV. Hepatology 2013;58:745A
    • (2013) Hepatology , vol.58
    • Popa, S.1    Berliba, A.2    Ghicavii, N.3
  • 101
    • 77955426384 scopus 로고    scopus 로고
    • Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus
    • McGuigan C, Madela K, Aljarah M, et al. Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus. Bioorg Med Chem Lett 2010;20:4850-4
    • (2010) Bioorg Med Chem Lett , vol.20 , pp. 4850-4854
    • McGuigan, C.1    Madela, K.2    Aljarah, M.3
  • 102
    • 79955529751 scopus 로고    scopus 로고
    • INX-08189, a phosphoramidate prodrug of 6-O-methyl-2-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties
    • Vernachio JH, Bleiman B, Bryant KD, et al. INX-08189, a phosphoramidate prodrug of 6-O-methyl-2-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties. Antimicrob Agents Chemother 2011;55:1843-51
    • (2011) Antimicrob Agents Chemother , vol.55 , pp. 1843-1851
    • Vernachio, J.H.1    Bleiman, B.2    Bryant, K.D.3
  • 103
    • 84906066665 scopus 로고    scopus 로고
    • In vitro characterization of the combination of daclatasvir, an NS5A inhibitor, and BMS-986094 (INX-08189), a precursor to an NS5B inhibitor
    • Li W, Gao M, Hall A, et al. In vitro characterization of the combination of daclatasvir, an NS5A inhibitor, and BMS-986094 (INX-08189), a precursor to an NS5B inhibitor. Hepatology 2012;56:1074A-5A
    • (2012) Hepatology , vol.56
    • Li, W.1    Gao, M.2    Hall, A.3
  • 104
    • 84892854326 scopus 로고    scopus 로고
    • A study of the safety and pharmacokinetics of single ascending oral doses of INX-08189, a nucleotide polymerase inhibitor, in healthy subjects
    • Patti J, Matson M, Boehlecke B, et al. A study of the safety and pharmacokinetics of single ascending oral doses of INX-08189, a nucleotide polymerase inhibitor, in healthy subjects. J Hepatol 2011;54:S187
    • (2011) J Hepatol , vol.54
    • Patti, J.1    Matson, M.2    Boehlecke, B.3
  • 105
    • 84906047769 scopus 로고    scopus 로고
    • Evaluation of potential pharmacokinetic drug-drug interaction between BMS-986094 (INX-08189) and verapamil when coadministered in healthy subjects
    • Campaneria R, Barry AN, Patti J, et al. Evaluation of potential pharmacokinetic drug-drug interaction between BMS-986094 (INX-08189) and verapamil when coadministered in healthy subjects. Hepatology 2012;56:1074A-A
    • (2012) Hepatology , vol.56
    • Campaneria, R.1    Barry, A.N.2    Patti, J.3
  • 106
    • 84890312082 scopus 로고    scopus 로고
    • Antiviral activity and safety of INX-08189, a nucleotide polymerase inhibitor, following 7-days of oral therapy in naive genotype-1 chronic HCV patients
    • Rodriguez-Torres M, Lawitz E, Hazan L, et al. Antiviral activity and safety of INX-08189, a nucleotide polymerase inhibitor, following 7-days of oral therapy in naive genotype-1 chronic HCV patients. Hepatology 2011;54:535A-A
    • (2011) Hepatology , vol.54
    • Rodriguez-Torres, M.1    Lawitz, E.2    Hazan, L.3
  • 107
    • 84892856547 scopus 로고    scopus 로고
    • BMS-986094 (INX-08189) plus peginterferon alfa-2a and ribavirin results in increased rates of rapid virologic response (RVR) and eRVR in treatment-naive HCV-genotype 2/3 patients compared to peginterferon alfa-2a and ribavirin: Week 12 results
    • Lawitz E, Lalezari J, Freilich B, et al. BMS-986094 (INX-08189) plus peginterferon alfa-2a and ribavirin results in increased rates of rapid virologic response (RVR) and eRVR in treatment-naive HCV-genotype 2/3 patients compared to peginterferon alfa-2a and ribavirin: Week 12 results. Hepatology 2012;56:566A-7A
    • (2012) Hepatology , vol.56
    • Lawitz, E.1    Lalezari, J.2    Freilich, B.3
  • 108
    • 84902940042 scopus 로고    scopus 로고
    • [Abstract MEDI 21 Abstracts of Papers of theftxt American Chemical Society 2012;244th National Meeting and Exposition
    • Cho A, Zhang L, Xu J, et al. Discovery of GS-6620: C-nucleoside HCV polymerase inhibitor [Abstract MEDI 21]. Abstracts of Papers of the American Chemical Society 2012;244th National Meeting and Exposition
    • Discovery of GS-6620: C-nucleoside HCV Polymerase Inhibitor
    • Cho, A.1    Zhang, L.2    Xu, J.3
  • 109
    • 84871152367 scopus 로고    scopus 로고
    • GS-6620: A liver targeted nucleotide prodrug with potent pan-genotype anti-hepatitis C virus activity in vitro
    • Ray AS, Feng JY, Wang T, et al. GS-6620: A liver targeted nucleotide prodrug with potent pan-genotype anti-hepatitis C virus activity in vitro. J Hepatol 2011;54:S487
    • (2011) J Hepatol , vol.54
    • Ray, A.S.1    Feng, J.Y.2    Wang, T.3
  • 110
    • 84879413512 scopus 로고    scopus 로고
    • GS-6620, a novel anti-hepatitis C virus nucleotide prodrug, has a high barrier to resistance in vitro
    • Fenaux M, Cheng G, Mabery E, et al. GS-6620, a novel anti-hepatitis C virus nucleotide prodrug, has a high barrier to resistance in vitro. J Hepatol 2011;54:S476
    • (2011) J Hepatol , vol.54
    • Fenaux, M.1    Cheng, G.2    Mabery, E.3
  • 111
    • 84873066836 scopus 로고    scopus 로고
    • Nucleotide inhibitor resistance selections using GT2A infectious virus: PSI-7851 and GS-6620 select for a novel resistance pathway including substitutions of M289V/L followed by S282T
    • Cheng G, Fenaux M, Mabery E, et al. Nucleotide inhibitor resistance selections using GT2A infectious virus: PSI-7851 and GS-6620 select for a novel resistance pathway including substitutions of M289V/L followed by S282T. J Hepatol 2011;54:S473
    • (2011) J Hepatol , vol.54
    • Cheng, G.1    Fenaux, M.2    Mabery, E.3
  • 112
    • 84906062823 scopus 로고    scopus 로고
    • Inhibition of hepatitis C virus replication by GS-6620, a potent c-nucleoside monophosphate prodrug
    • Feng JY, Cheng G, Perry J, et al. Inhibition of hepatitis C virus replication by GS-6620, a potent c-nucleoside monophosphate prodrug. Antimicrob Agents Chemother 2014;13:13
    • (2014) Antimicrob Agents Chemother , vol.13 , pp. 13
    • Feng, J.Y.1    Cheng, G.2    Perry, J.3
  • 113
    • 84870435875 scopus 로고    scopus 로고
    • GS-6620, a liver-Targeted nucleotide prodrug, exhibits antiviral activity and favorable safety profile over 5 days in treatment naive chronic HCV genotype 1 subjects
    • Lawitz E, Hill J, Marbury T, et al. GS-6620, a liver-Targeted nucleotide prodrug, exhibits antiviral activity and favorable safety profile over 5 days in treatment naive chronic HCV genotype 1 subjects. J Hepatol 2012;56:S470-S71
    • (2012) J Hepatol , vol.56
    • Lawitz, E.1    Hill, J.2    Marbury, T.3
  • 114
    • 84906057528 scopus 로고    scopus 로고
    • Metabolism and pharmacokinetics of the anti-HCV nucleotide prodrug GS-6620
    • Murakami E, Wang T, Babusis D, et al. Metabolism and pharmacokinetics of the anti-HCV nucleotide prodrug GS-6620. Antimicrob Agents Chemother 2014;13:13
    • (2014) Antimicrob Agents Chemother , vol.13 , pp. 13
    • Murakami, E.1    Wang, T.2    Babusis, D.3
  • 115
    • 84906057968 scopus 로고    scopus 로고
    • Preclinical characteristics of ACH-3422: A potent uridine nucleotide prodrug for inhibition of hepatitis C virus polymerase
    • Yang W, Wiles J, Patel D, et al. Preclinical characteristics of ACH-3422: A potent uridine nucleotide prodrug for inhibition of hepatitis C virus polymerase. Hepatology 2013;58:436A
    • (2013) Hepatology , vol.58
    • Yang, W.1    Wiles, J.2    Patel, D.3
  • 116
    • 84906060891 scopus 로고    scopus 로고
    • Discovery and preclinical profiling of LG-7501, a liver-Targeted hepatitis C virus (HCV) nucleotide NS5B polymerase inhibitor designed to improve clinical efficacy and safety
    • Vajda EG, Marschke KB, Henderson I, et al. Discovery and preclinical profiling of LG-7501, a liver-Targeted hepatitis C virus (HCV) nucleotide NS5B polymerase inhibitor designed to improve clinical efficacy and safety. Hepatology 2012;56:1080A-A
    • (2012) Hepatology , vol.56
    • Vajda, E.G.1    Marschke, K.B.2    Henderson, I.3
  • 117
    • 84906047032 scopus 로고    scopus 로고
    • HepDirect (TM) improves liver-Targeting of HCV nucleotide NS5B polymerase inhibitor LG-7501 versus phosphoramidate pronucleotide technology
    • Vajda EG, Marschke KB, Zhi L. HepDirect (TM) improves liver-Targeting of HCV nucleotide NS5B polymerase inhibitor LG-7501 versus phosphoramidate pronucleotide technology. J Hepatol 2013;58:S498-S99
    • (2013) J Hepatol , vol.58
    • Vajda, E.G.1    Marschke, K.B.2    Zhi, L.3
  • 118
    • 84906046479 scopus 로고    scopus 로고
    • Antiviral activity of EP-NI266, a potent nucleotide HCV polymerase inhibitor
    • Owens CM, Rhodin MHJ, Polemeropoulos A, et al. Antiviral activity of EP-NI266, a potent nucleotide HCV polymerase inhibitor. J Hepatol 2012;56:S475-S76
    • (2012) J Hepatol , vol.56
    • Owens, C.M.1    Rhodin, M.H.J.2    Polemeropoulos, A.3
  • 119
    • 84884127794 scopus 로고    scopus 로고
    • All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear
    • Lawitz EJ, Rodriguez-Torres M, Denning J, et al. All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear). J Viral Hepat 2013;20:699-707.
    • (2013) J Viral Hepat , vol.20 , pp. 699-707
    • Lawitz, E.J.1    Rodriguez-Torres, M.2    Denning, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.